Related Experiment Video
Updated: Jul 28, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial
Masoud Maleki1, Pouran Layegh1, Bita Kiafar1
1Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction:
Basal cell carcinoma (BCC) is the most common cutaneous cancer. We report the efficacy and aesthetic outcome of intralesional IFN-α 2b injection for the treatment of BCC and compare with the surgical method.
Materials And Methods:
Intralesional IFN-α 2b was injected in 58 BCC lesions from 20 patients three times a week for three weeks. Control group was retrospectively selected among patients who underwent surgical method (standard surgical excision) for BCC including 58 lesions from 24 patients. All patients were followed up for one year in terms of recurrence and cosmetic outcome.
Results:
Two patients (four lesions) failed to complete the treatment period. After three weeks, 40 (68.96%) lesions were completely cured. Nine (15.51%) lesions achieved complete healing in less than 9 sessions. Five (8.62%) lesions were completely cured by an extra week of injection. In aggregate, complete healing was observed in 54 (93.10%) lesions. In the surgery group, complete lesion elimination was detected in 52 (89.65%) lesions (p = 0.40). After one year, cosmetic outcome was significantly more favorable in the study group compared to the surgery group (p = 0.003). Recurrence was not detected in any of the groups after one year follow-up.
Conclusion:
Intralesional IFN-α 2b injection is an appropriate treatment choice for BCC.
Clinical Trial Registry:
We used Iranian registery of Clinical trials; The IRCT code is: 2017093017756N30.
